Mice Model Market: Market Size & Forecast 2026

The mice model market consists of laboratory-bred mice specifically designed for scientific research, serving as critical tools in preclinical drug discovery, toxicology testing, and disease modeling. These models range from standard inbred strains with consistent genetic backgrounds to sophisticated genetically engineered mice that carry human disease genes, have specific gene knockouts, or express reporter proteins for research visualization.

• •Models include inbred mice, hybrid mice, outbred mice, and genetically engineered variants such as knockout and transgenic mice
• •Primary applications span cancer research, immunology, neuroscience, endocrinology, and cardiovascular studies
• •End users include pharmaceutical and biotechnology companies, academic research institutions, government research agencies, and contract research organizations

The market expansion is fueled by several key factors, including increased R&D spending in the pharmaceutical and biotechnology sectors that drives demand for animal models in drug development pipelines. Rising prevalence of chronic diseases such as cancer, diabetes, and neurological disorders necessitates continued research into disease mechanisms and therapeutic interventions.

• •Growing adoption of personalized medicine and targeted therapies requiring humanized and genetically customized mouse models
• •Increased government and private funding for biomedical research, particularly in emerging markets
• •Expansion of immuno-oncology research driving demand for immunodeficient and humanized mouse models to study immune responses and test immunotherapies

The market is segmented by model type, including inbred mice, hybrid mice, outbred mice, and genetically engineered mice such as knockout and transgenic varieties. Geographically, North America holds the largest market share due to strong research infrastructure, high pharmaceutical R&D investment, and the presence of major research institutions.

• •North America leads market share, followed by Europe and the Asia-Pacific region, which is experiencing the fastest growth
• •Asia-Pacific growth is driven by increasing R&D investment in countries like China, Japan, and South Korea, as well as outsourcing of research services
• •Immunodeficient mice and genetically engineered models represent the fastest-growing segments due to their critical role in advanced research applications

What are the recent trends and outlook?

The market is witnessing increased adoption of CRISPR-Cas9 and other advanced gene editing technologies to create more precise disease models with shorter development timelines. Demand for humanized mice, which carry human gene sequences or immune systems, is growing to support immuno-oncology research and better predict human drug responses.

• •Growing trend toward personalized mouse models that replicate specific patient genetic profiles for precision medicine research
• •Integration of artificial intelligence and machine learning in phenotyping and genotyping to accelerate model characterization
• •The market is expected to maintain its 10.0% CAGR trajectory through 2030, reaching approximately $2.74 billion in value